The Claim
Daily administration of liraglutide 3 mg for 32 weeks increases the proportion of obese women with polycystic ovary syndrome achieving at least 5% weight loss to 56.8% compared to 21.7% with placebo, indicating clinically meaningful metabolic improvement.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese women with polycystic ovary syndrome, taking liraglutide 3 mg daily for 32 weeks results in 56.8% achieving at least 5% weight loss, while 21.7% achieve this with a placebo.
See the scientific wording
Liraglutide 3 mg daily for 32 weeks increases the proportion of obese women with polycystic ovary syndrome achieving at least 5% weight loss to 56.8% compared to 21.7% with placebo, demonstrating clinically meaningful metabolic improvement.
Liraglutide activates receptors in the brain and pancreas that reduce hunger, slow digestion, and improve insulin control. Lower insulin levels decrease fat storage and stop the ovaries from making too much testosterone. This reduces belly fat, improves how the body uses insulin, and allows the body to burn more fat, leading to significant weight loss.
What the research says
1 studyIn a study of obese women with PCOS, half of those taking liraglutide lost at least 5% of their body weight, while only about 1 in 5 on a dummy pill did — showing the drug really helps with weight loss.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.